Are female patients with lupus who take Hydroxychloroquine at an increased risk for adverse cardiovascular events compared to those taking other lupus management drugs?
Abstract
HCQ use in female SLE patients is associated with a lower risk of adverse cardiovascular events compared to non-use, though direct comparisons with other lupus drugs are limited.
Fields of Study & Subjects
Systemic Lupus Erythematosus Research
Drug-Induced Ocular Toxicity
Rheumatoid Arthritis Research and Therapies
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 5 January 2026